CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis Potential Mechanisms of In-stent Neointimal Atherosclerotic Plaque Formation Low shear stress induces vascular eNOS uncoupling via autophagy-mediated eNOS phosphorylation Optimizing outcomes during left main percutaneous coronary intervention with intravascular ultrasound and fractional flow reserve: the current state of evidence Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial The right ventricle in pulmonary hypertension Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club Outcomes of procedural complications in transfemoral transcatheter aortic valve replacement

Expert Opinion2017 Feb 28;135(9):819-821.

JOURNAL:Circulation Article Link

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?

Gersh BJ, Stone GW, Bhatt DL et al. Keywords: coronary artery bypass grafting; coronary artery disease; stenting

ABSTRACT

Approximately 60 randomized controlled trials performed over the last 3 decades have failed to demonstrate statistically significant differences in death or myocardial infarction (MI) between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), apart from a few notable exceptions in which CABG was superior to PCI. The benefits for CABG have been reported in patients with diabetes mellitus with multivessel disease and in patients with and without diabetes mellitus with 3-vessel disease and intermediate or high SYNTAX trial (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) scores (≥23).